Enhancing arrest of cell growth to treat cancer in mice

Feb 08, 2010

A team of researchers, led by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical Center, Boston, has identified a new type of cellular senescence (i.e., irreversible arrest of cell growth) and determined a way to enhance it to suppress prostate tumor development and growth in mice.

Previous work by Pandolfi and colleagues determined that inactivation of the protein Pten leads to a senescence response that opposes tumorigenesis.

In this study, Pten-loss-induced cellular senescence (PICS) was found to be distinct from another form of cellular senescence known as oncogene-induced senescence in that it did not cause cellular proliferation and . This was important because these two consequences of oncogene-induced senescence mean that enhancing this process for the treatment of cancer is not a viable option.

As pharmacological inhibition of PTEN was found to drive senescence and inhibit and growth in vivo in a human xenograft model of , the authors suggest that enhancing PICS might provide a new approach for cancer prevention and therapy.

Explore further: Death from cancer more likely in New Zealand

More information: A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. View this article at: www.jci.org/articles/view/4053… 9b25621b73ed2877356a

Provided by Journal of Clinical Investigation

4 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Preventing cancer without killing cells

Mar 30, 2007

Inducing senescence in aged cells may be sufficient to guard against spontaneous cancer development, according to a paper published online this week in EMBO reports. It was previously unknown whether cellular senescence or ...

DNA damage response confers a barrier for viral tumorigenesis

Sep 28, 2007

Kaposi’s sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi’s sarcoma (KS). KSHV infection is endemic in sub-Saharan Africa where KS is nowadays the most common malignancy, due to widespread ...

Blocking beta1-integrin to treat cancer

Jun 06, 2007

Targeting the function of a protein known as beta1-integrin might represent a novel approach to cancer treatment, according to a paper published online in The EMBO Journal this week. Blocking the action of this protein could ...

Rheb's role in cancer

Aug 14, 2008

Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.

Recommended for you

Endogenous hormones improve breast cancer risk models

10 hours ago

(HealthDay)—Inclusion of endogenous hormones in prediction models improves prediction of invasive breast cancer risk in postmenopausal women, according to a study published online Aug. 18 in the Journal of ...

Novel oncogenic RET mutation found in small cell lung cancer

11 hours ago

For the first time an oncogenic somatic mutation at amino acid 918 in the RET (rearranged during transfection) protein has been identified in small cell lung cancer (SCLC) tumors and enforced expression of this mutation within ...

User comments : 0